» Articles » PMID: 11023601

Comparative Risk Assessment of Secondary Cancer Incidence After Treatment of Hodgkin's Disease with Photon and Proton Radiation

Overview
Journal Radiat Res
Specialties Genetics
Radiology
Date 2000 Oct 7
PMID 11023601
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Probabilities for secondary cancer incidence have been estimated for a patient with Hodgkin's disease for whom treatment has been planned with different radiation modalities using photons and protons. The ICRP calculation scheme has been used to calculate cancer incidence from dose distributions. For this purpose, target volumes as well as critical structures have been outlined in the CT set of a patient with Hodgkin's disease. Dose distributions have been calculated using conventional as well as intensity-modulated treatment techniques using photon and proton radiation. The cancer incidence has been derived from the mean doses for each organ. The results of this work are: (a) Intensity-modulated treatment of Hodgkin's disease using nine photon fields (15 MV) results in nearly the same cancer incidence as treating with two opposed photon fields (6 MV). (b) Intensity-modulated treatment using nine proton fields (maximum energy 177.25 MeV) results in nearly the same cancer incidence as treating with one proton field (160 MeV). (c) Irradiation with protons using the spot scanning technique decreases the avoidable cancer incidence compared to photon treatment by a factor of about two. This result is independent of the number of beams used. Our work suggests that there are radiotherapy indications in which intensity-modulated treatments will result in little or no reduction of cancer incidence compared to conventional treatments. However, proton treatment can result in a lower cancer incidence than photon treatment.

Citing Articles

Monte Carlo-Based Radiobiological Investigation of the Most Optimal Ion Beam Forming SOBP for Particle Therapy.

Kantemiris I, Pappas E, Lymperopoulou G, Thanasas D, Karaiskos P J Pers Med. 2023; 13(1).

PMID: 36675684 PMC: 9864401. DOI: 10.3390/jpm13010023.


Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group.

Giulino-Roth L, Pei Q, Buxton A, Bush R, Wu Y, Wolden S Blood. 2021; 137(11):1449-1456.

PMID: 33512412 PMC: 7976513. DOI: 10.1182/blood.2020007225.


Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk.

Konig L, Haering P, Lang C, Splinter M, von Nettelbladt B, Weykamp F Front Oncol. 2020; 10:989.

PMID: 32733794 PMC: 7358352. DOI: 10.3389/fonc.2020.00989.


Out-of-Field Dose Calculation by a Commercial Treatment Planning System and Comparison by Monte Carlo Simulation for Varian TrueBeam.

Shine N, Paramu R, Gopinath M, Jaon Bos R, Jayadevan P J Med Phys. 2019; 44(3):156-175.

PMID: 31576064 PMC: 6764172. DOI: 10.4103/jmp.JMP_82_18.


Evaluation of Breast Cancer Radiation Therapy Techniques in Outfield Organs of Rando Phantom with Thermoluminescence Dosimeter.

Behmadi M, Gholamhosseinian H, Mohammadi M, Naseri S, Momennezhad M, Bayani S J Biomed Phys Eng. 2019; 9(2):179-188.

PMID: 31214523 PMC: 6538909.